[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588122":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":69,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","SABR treatment to Whole breast +\u002F- regional lymph nodes",[13],"Radiation: SABR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","SABR","Prescription dose\u002Ffractionation: 26Gy\u002F5 with 40Gy\u002F5 +\u002F- 35Gy\u002F5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Sandy Chang","CONTACT","6048776000","sandy.chang@bccancer.bc.ca",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"BC Cancer - Vancouver","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":36,"coordinates":37},"Point",[38,39],-123.11934,49.24966,{"lat":39,"lon":38},[42,43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":44,"role":45,"phone":20,"phoneExt":20,"email":20},"Andrew Bang, MPH MD FRCSC","PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100588122","sabr-primer---evaluating-stereotactic-ablative-radiotherapy-for-primary-and-regional-breast-tumors-100588122",false,"NCT06937281","SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors","A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors (SABR-PRIMeR)","SABR PRIMER","Inclusion Criteria:\n\n1. Pathologically confirmed AJCC 7th\u002F8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.\n2. Measurable disease in the breast, suitable to receive radiotherapy.\n3. Receiving or planned to receive systemic therapy.\n\n   a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4\u002F6 inhibitors, T-DXd\n4. Patients are allowed to have SABR for oligometastatic disease as clinically indicated\n5. Age 18 or older\n6. ECOG Performance Status 0-2\n7. Life expectancy greater than 6 months\n8. Able and willing to provide informed consent\n9. Able to complete patient reported outcome questionnaires\n\nExclusion Criteria:\n\n1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy\n2. Previous history of locoregional radiotherapy to the ipsilateral breast","ALL","18 Years",{"count":59,"type":60},40,"ESTIMATED","INTERVENTIONAL",[63],"NA","The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.\n\nSecondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy.\n\nRadiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy.\n\nThe exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.",[66,67],"Breast Cancer","Metastases",[17],"NOT_YET_RECRUITING","2025-04-22",{"date":72,"type":73},"2025-04-24","ACTUAL",{"date":75,"type":60},"2025-07-01",{"date":77,"type":60},"2030-07-30",{"name":5,"class":6},1]